Vanda Sets $240 Million-Plus 2026 Revenue Goal, Plans Q4 BYSANTI Launch

John Kim

1 min read

Add as a preferred source on Google

Vanda Sets $240 Million-Plus 2026 Revenue Goal, Plans Q4 BYSANTI Launch

Vanda’s third-quarter revenue increased 24% year over year.

By John Kim

Published Oct 29, 2026, 3:24 AM EDT

An unmarked medicine carton rests on an empty pharmacy shelf / TokenPost.ai

Vanda Pharmaceuticals Inc. said it is targeting more than $240 million in revenue for 2026 and plans to launch BYSANTI in the fourth quarter.

Management linked the third-quarter results to continued momentum from Fanapt and an early contribution from NEREUS, whose commercial launch had recently begun. HETLIOZ and PONVORY also contributed to revenue.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.